ERBB2 and breast carcinoma: The signature also predicted better RFS (HR = 0.69 (0.48–0.98), logrank P = 0.037) for Luminal A, but not for Luminal B as well as neither predicted OS nor DMFS for Luminal A nor Luminal B breast cancer patients, suggesting its selectivity in predicting Basal, and to a lesser extent, HER2+ breast cancer patient outcomes (Figure 8, third and fourth panels).